Abstract
Comprehensively studying metabolism requires the measurement of metabolite levels. However, in contrast to the broad availability of gene expression data, metabolites are rarely measured in large molecularly-defined cohorts of tissue samples. To address this basic barrier to metabolic discovery, we propose a Bayesian framework (“UnitedMet”) which leverages the empirical strength of RNA-metabolite covariation to impute otherwise unmeasured metabolite levels from widely available transcriptomic data. We demonstrate that UnitedMet is equally capable of imputing whole pool sizes as well as the outcomes of isotope tracing experiments. We apply UnitedMet to investigate the metabolic impact of driver mutations in kidney cancer, identifying a novel association between BAP1 and a highly oxidative tumor phenotype. We similarly apply UnitedMet to determine that advanced kidney cancers upregulate oxidative phosphorylation relative to early-stage disease, that oxidative metabolism in kidney cancer is associated with inferior outcomes to combination therapy, and that kidney cancer metastases themselves demonstrate elevated oxidative phosphorylation relative to primary tumors. UnitedMet therefore enables the assessment of metabolic phenotypes in contexts where metabolite measurements were not taken or are otherwise infeasible, opening new avenues for the generation and evaluation of metabolite-centered hypotheses. UnitedMet is open source and publicly available (https://github.com/reznik-lab/UnitedMet).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was generously supported by the Cycle for Survival, the Marie-Josee and Henry R. Kravis Center for Molecular Oncology and the National Cancer Institute Cancer Center Core (grant P30-CA008748) supporting Memorial Sloan Kettering Cancer Center. E.R. was supported by the Department of Defense Kidney Cancer Research Program (W81XWH-18-1-0318 and HT9425-23-1-0995), Cycle For Survival Equinox Innovation Award, Kidney Cancer Association Young Investigator Award, Brown Performance Group Innovation in Cancer Informatics Fund and NIH (R37 CA276200). E.R. was also supported by a grant from the Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center. W.T. is supported by the NIH/NCI (R37 CA271186, U54 CA274492, P30 CA008748), Break Through Cancer, and the Tow Center for Developmental Oncology.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
(1) Processed metabolomics and RNA-seq data for RC18 and RC20 are publicly available at https://doi.org/10.5281/zenodo.7150252. (2) Metabolite raw count matrices of CPTAC (n=50) and CPTAC_val (n=71) were downloaded from Li et al (https://pubmed.ncbi.nlm.nih.gov/36563681/). Transcriptomic and WES data were downloaded from Genomic Data Commons (GDC) at: https://portal.gdc.cancer.gov/projects/CPTAC-3 (Project: CPTAC-3, Primary Site: Kidney). (3) Paired RNA-seq and isotopic labeling data from 76 primary tumor or adjacent normal kidney samples of RCC patients were downloaded from Bezwada et al (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934542/). (4) We downloaded paired RNA-seq and WES data of 1020 RCC tumor and adjacent normal samples in TCGA KIPAN from the Genome Data Analysis Center (GDAC) in Broad Institute (http://firebrowse.org/). (5) mtDNA mutation calls using a Polymerase Chain Reaction (PCR)-based amplification approach for 61 ChRCC cases in TCGA KICH were downloaded from Davis et al (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160352/). (6) We collected RNA-seq data and patient-level clinical information from IMmotion151 (N=823), a published trial exploring immunotherapeutic versus systemic agents in advanced ccRCC (https://pubmed.ncbi.nlm.nih.gov/33157048/, https://pubmed.ncbi.nlm.nih.gov/34940781/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
In the revised manuscript, I updated the funding statement.
Data Availability
All data needed to evaluate the conclusions in the paper are present in the paper and/or available online at 10.5281/zenodo.11286535. UnitedMet is open-source and online at: https://github.com/reznik-lab/UnitedMet.
